Biotech Winners: King Pharmaceuticals, Pain Therapeutics
(Biotech winners and losers item updated for stock closing stock prices.)
NEW YORK (TheStreet) -- Pain relief became the theme of Tuesday's trading session in biotech land, after Pfizer's (PFE) $3.6 billion deal to acquire King Pharmaceuticals (KG), a pain-reliever specialist, came to light before the opening bell.
The news drove King's stock to the cusp of Pfizer's offer price -- the equivalent of $14.25 a share, a 40% premium to the Monday close. Shares of the Bristol, Tenn.-based King, which also does a robust business in veterinary medicine, ended trading at $14.14, up 39%, or $3.99. More than a quarter of a billion King shares changed hands Tuesday, almost 100 times the daily average.
The deal also helped the shares of an early-stage painkiller developer with a rather literal name: Pain Therapeutics (PTIE), which has teamed with King on the development of Pain's lead drug candidate, called Remoxy, currently in clinical trials.The two companies also have a licensing agreement for Remoxy, a "strong painkiller," Pain says in its press materials, the main selling point of which appears to be that it has a "unique formulation designed to reduce potential risks of unintended use." In other words, the Remoxy recipe, delivered as a capsule, makes it hard for users to binge on the drug and get addicted to its painkiller qualities. Investors and traders were apparently excited by the notion of a global Pfizer sales and marketing force pushing Remoxy into the dreamed-for blockbuster realm. King was slated to submit a new drug application for Remoxy with the Food and Drug Administration sometime during the fourth quarter. Pain shares closed Tuesday up 18.6% to $7.41. Volume exceeded one million shares, 14 times the daily average turnover in this normally lightly traded name. Similarly, investors bid up shares of Acura Pharmaceuticals (ACUR) in light of the company's partnership with King to develop another pain reliever meant to prevent abuse. Acura shares, also fairly illiquid, ended the day up 12% to $2.55.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV